JPMorgan raised the firm’s price target on Apellis (APLS) to $54 from $50 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $29 from $30 at Wedbush
- Positive Long-term Outlook and Strategic Positioning Drive Buy Rating for Apellis Pharmaceuticals
- Apellis price target lowered to $44 from $47 at BofA
- Apellis price target lowered to $30 from $31 at Morgan Stanley
- Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance